Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Rambam Maimonides Med J ; 12(1)2021 Jan 19.
Artigo em Inglês | MEDLINE | ID: mdl-33478628

RESUMO

Transverse myelitis is an inflammatory lesion of the spinal cord, occurring in different autoimmune, infectious, and traumatic diseases but is the hallmark of neuromyelitis optica (NMO), a rare neurologic autoimmune disease. Patients with systemic lupus erythematosus (SLE) may develop transverse myelitis as a neuropsychiatric complication of active disease; however, at times, NMO co-exists as an additional primary autoimmune condition in a SLE patient. Correct diagnosis of a SLE-NMO overlap is important not only for the different disease course and prognosis compared with SLE-related LETM, but especially for the emerging and highly specific NMO treatment options, not established for SLE-related LETM-such as anti-aquaporin 4 antibodies, anti-VEGF antibodies, complement modulation, or IVIg.

2.
Br J Haematol ; 153(3): 372-8, 2011 May.
Artigo em Inglês | MEDLINE | ID: mdl-21401572

RESUMO

Patients with type I Gaucher Disease (GD) may have a clinically significant bleeding tendency that is disproportionate to their platelet count. We hypothesized that impaired platelet adhesion might contribute to bleeding tendency. Adult patients with type I GD with platelet counts ≥130×10(9) /l and haematocrit ≥30% (n=48), obligatory carriers (n=52), and healthy controls (n=19) were studied. Platelet adhesion, using the IMPACT-R (Cone and Plate(let) Analyser), and platelet aggregation were determined. Type I GD patients had significantly lower platelet adhesion [surface coverage %, median (interquartile range)] 4·6 (3·2-7·5), compared to controls, 8·7 (7·6-10·3), or carriers, 8·1 (6·5-9·4; P=0·001). Platelet adhesion was not affected by the use of disease-specific enzyme replacement therapy but was improved in patients after splenectomy, 7·2 (5·8-9·3). Mixing tests showed that the reduced adhesion was an intrinsic platelet defect. Mucosal bleeding was reported in 17 (35·4%) patients and was associated with abnormal adhesion [P=0·037, with an Odds Ratio (95% confidence interval) of 5·73 (1·1-29·6)]. Five patients (22%) had reduced platelet aggregation, all of whom had reduced platelet adhesion. Platelet aggregation defect was not associated with mucosal bleeding. In conclusion, platelet adhesion defect is a major thrombocytopathy in type I GD patients and can explain part of the increased tendency to bleeding.


Assuntos
Transtornos Plaquetários/etiologia , Doença de Gaucher/complicações , Hemorragia/etiologia , Adesividade Plaquetária/fisiologia , Adulto , Contagem de Células Sanguíneas , Transtornos Plaquetários/sangue , Terapia de Reposição de Enzimas/métodos , Feminino , Doença de Gaucher/sangue , Doença de Gaucher/terapia , Glucosilceramidase/uso terapêutico , Hemorragia/sangue , Humanos , Masculino , Pessoa de Meia-Idade , Agregação Plaquetária/fisiologia , Contagem de Plaquetas , Testes de Função Plaquetária , Esplenectomia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA